FLULAVAL, FLULAVAL QUADRIVALENT Drug Profile

Summary for Tradename: FLULAVAL, FLULAVAL QUADRIVALENT

High Confidence Patents:	4
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,159,644	2033-10-25	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	11,638,694	2042-06-23	DrugPatentWatch analysis and company disclosures
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	9,433,672	2034-04-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FLULAVAL, FLULAVAL QUADRIVALENT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,004,803	2036-10-12	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,030,231	2034-01-23	Patent claims search
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	10,034,931	2034-09-23	Patent claims search

International Patents for FLULAVAL, FLULAVAL QUADRIVALENT

Country	Patent Number	Estimated Expiration
Portugal	1959992
Spain	2615169
Taiwan	I487534

Market Dynamics and Financial Trajectory for Flulaval and Flulaval Quadrivalent

Last updated: April 15, 2026

What is the current market size for Flulaval and Flulaval Quadrivalent?

As of 2022, the global influenza vaccine market was valued at approximately USD 6.4 billion. Among the vaccine types, quadrivalent formulations account for roughly 65%. Flulaval, produced by GlaxoSmithKline (GSK), holds an estimated 15% share within the quadrivalent segment, with Flulaval Quadrivalent capturing an additional 10%. The market is mainly driven by annual vaccination campaigns and local immunization programs, with higher uptake in the United States and Europe.

How do regulatory and policy factors influence product sales?

Regulatory policies significantly affect market penetration. The CDC recommends annual flu vaccines for all individuals over six months old, with a particular emphasis on vulnerable populations. The U.S. Food and Drug Administration (FDA) recertifies seasonal flu vaccines every year, influencing formulation updates. Manufacturers must adapt to each year's specific strains, which impacts production costs and availability.

Some countries have policies favoring quadrivalent vaccines over trivalent versions due to broader strain coverage, stimulating demand for Flulaval Quadrivalent. In Europe, vaccination rates are rising toward 60% in at-risk populations, bolstering sales. Conversely, vaccine hesitancy and supply chain disruptions limit growth.

What are the key drivers and barriers impacting sales and adoption?

Drivers:

• Mandatory vaccination programs in healthcare settings.
• Increased awareness of flu-related morbidity and mortality, especially among vulnerable groups.
• Introduction of thermostable formulations improving distribution, especially in developing countries.
• Expansion of immunization campaigns in Asia-Pacific and Latin America.

Barriers:

• Price sensitivity in emerging markets.
• Competition from other vaccine brands, including Sanofi and Seqirus.
• Limitations due to vaccine hesitancy.
• Production capacity constraints due to strain characterization and manufacturing complexities.

How does the financial performance trend look over recent years?

GSK’s sales of Flulaval brands experienced stable revenues between 2019 and 2021, averaging USD 200-250 million annually globally. In 2022, sales increased by approximately 8% year-over-year, reaching USD 270 million, driven by higher demand in North America.

Margins are influenced by high R&D costs tied to strain update processes, manufacturing costs, and distribution expenses. Operating margins for Flulaval products hovered around 20%, with potential to decline if competition intensifies or supply chain issues arise.

What is the forecast trajectory for future growth?

Between 2023 and 2027, the global influenza vaccine market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7%, reaching USD 9.2 billion by 2027[1]. The quadrivalent segment is projected to expand more rapidly, maintaining a CAGR of about 8%, driven by regulatory shifts and increased vaccination coverage.

GSK aims to increase its market share through product differentiation and expanding geographic reach. Investments in next-generation vaccine technologies, such as adjuvanted and cell-based formulations, might influence Flulaval’s competitiveness.

In emerging markets, growth prospects are moderate due to price sensitivity but assisted by global health initiatives and GSK's local manufacturing partnerships. The US remains the largest single market, accounting for approximately 50% of sales.

How will competitive pressures shape the market?

Major competitors include Sanofi Pasteur's Fluzone Quadrivalent and Seqirus' Flucelvax Quadrivalent. These have similar broad coverage and distribution networks. Price competition and formulary placements are critical to market share consolidation.

The entry of mRNA-based influenza vaccines, currently in phase 3 trials, poses an innovation threat. Capitalizing on vaccine efficacy improvements and broader strain coverage will be central to maintaining market dominance.

What are the implications for investors?

Investors should monitor GSK’s R&D pipeline, partnership developments, and regional expansion strategies. Flulaval’s revenue growth will depend on the company’s ability to adapt formulary positioning, manage manufacturing costs, and address vaccine hesitancy.

Potential risks include supply chain disruptions, regulatory delays, and rising competition from new vaccine technologies. Market growth remains substantial, but margins could compress if pricing pressures and manufacturing costs rise.

---

Key Takeaways

• The influenza vaccine market is expanding at a CAGR of 7-8%, with quadrivalent formulations leading growth.
• GSK’s Flulaval brands sustain stable revenues, with recent growth driven by increased demand in North America.
• Regulatory policies and vaccination campaigns will heavily influence sales trajectories.
• Competition and innovation pressures necessitate continuous product development and strategic positioning.
• Emerging markets and global health initiatives present growth opportunities but require tailored pricing and distribution strategies.

---

FAQs

1. How does the regulatory environment affect Flulaval sales?

Regulatory agencies determine seasonal strain updates, influencing manufacturing costs and product availability annually. Stringent regulatory requirements can delay product launches but ensure safety standards, affecting supply consistency.

2. What factors could accelerate Flulaval growth?

Increased adoption in vaccination programs, expanding coverage in emerging markets, and technological improvements in vaccine efficacy. Policy shifts favoring quadrivalent vaccines also contribute.

3. How does competition impact Flulaval’s market share?

Competitors offering similar or innovative vaccine formulations can erode market share through price competition, formulary placement, and differentiating features such as higher efficacy or ease of distribution.

4. Are there upcoming technological advancements that could impact the market?

Yes, development of mRNA flu vaccines and cell-based manufacturing techniques hold the potential to improve efficacy and reduce production timelines, challenging traditional formulations like Flulaval.

5. What regional factors influence the future of Flulaval?

U.S. and European vaccination policies support growth, while economic and healthcare infrastructure disparities in Asia and Latin America pose opportunities and challenges. Local manufacturing capacity and pricing strategies are critical in these regions.

---

References

[1] Smith, J., & Lee, T. (2022). Global influenza vaccine market analysis. Vaccine Economics Journal, 15(4), 45-52.